GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty

BACKGROUND: Gonadotropin-releasing hormone agonist (GnRHa) is the gold standard in the treatment of Central Precocious Puberty (CPP) with progressive puberty and accelerative growth. However, GnRHa treatment is reported to result in growth deceleration and prevents growth plate development which lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Shunye, Long, Lingli, Hu, Yue, Tuo, Ying, Li, Yubin, Yu, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221533/
https://www.ncbi.nlm.nih.gov/pubmed/34177807
http://dx.doi.org/10.3389/fendo.2021.678797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221533/
https://www.ncbi.nlm.nih.gov/pubmed/34177807
http://dx.doi.org/10.3389/fendo.2021.678797

Ejemplares similares